Pentixapharm Holding AG (PTP) | Finanzwire

Basculer en Français

8295	Companies
114831	Keywords
55272	Articles
62429	Press releases

Headlines Articles Press releases Pentixapharm Holding AG

Home
Companies
Pentixapharm Holding AG

BRIEF

published on 11/12/2024 at 17:50, 8 days 16 hours ago

Pentixapharm Reports Third Quarter 2024 Interim Results

Interim Report Spin-off Financial Loss Third Quarter Pentixapharm
PRESS RELEASE

published on 11/12/2024 at 17:45, 8 days 16 hours ago

Pentixapharm Releases Interim Report for the Third Quarter of 2024
Pentixapharm Holding AG releases interim report for third quarter of 2024, reporting a loss of €49k with no revenue. Anticipates significant increase in losses for 2024 consolidated annual financial statements

Financial Statements Revenue Interim Report Loss Pentixapharm
BRIEF

published on 11/04/2024 at 17:31, 16 days 17 hours ago

Pentixapharm Applauds CMS Reimbursement Enhancement for Radiopharmaceuticals

Radiopharmaceuticals Pentixapharm CMS Decision Reimbursement Policy Diagnostic Innovation
PRESS RELEASE

published on 11/04/2024 at 17:26, 16 days 17 hours ago

Pentixapharm Welcomes CMS Decision to Enhance Reimbursement for Diagnostic Radiopharmaceuticals
Pentixapharm welcomes CMS decision to enhance reimbursement for diagnostic radiopharmaceuticals, which could impact future streams for Ga68-PentixaFor and have broader market implications

Radiopharmaceuticals Reimbursement Pentixapharm Ga68-PentixaFor CMS Decision
BRIEF

published on 10/29/2024 at 11:51, 22 days 22 hours ago

Pentixapharm's PentixaFor Enters Advanced US Clinical Trials

Clinical Trial Pentixapharm PentixaFor Adrenal Tumors PET Scans
PRESS RELEASE

published on 10/29/2024 at 11:46, 22 days 22 hours ago

Pentixapharm Holding AG: US National Cancer Institute Starts Advanced Clinical Trial with PentixaFor
US National Cancer Institute initiates clinical trial with PentixaFor, a new radioactive tracer, to aid in identifying adrenal tumors through PET scans, potentially benefiting patients with aldosteronism and Cushing's syndrome

Clinical Trial PentixaFor Adrenal Tumors PET Scans NIH
BRIEF

published on 10/28/2024 at 12:31, 23 days 22 hours ago

Nuclear Medicine Expert Ken Herrmann Joins Pentixapharm's Board

Supervisory Board Nuclear Medicine Radiopharmaceuticals Oncology Pipeline Ken Herrmann
PRESS RELEASE

published on 10/28/2024 at 12:26, 23 days 22 hours ago

Nuclear Medicine Specialist Ken Herrmann Joins Supervisory Board of Pentixapharm Holding AG
Nuclear Medicine Specialist Ken Herrmann joins Pentixapharm Holding AG's Supervisory Board, bringing expertise in radiopharmaceuticals and theranostics. His appointment aims to advance oncology pipeline

Oncology Nuclear Medicine Radiopharmaceuticals Pentixapharm Ken Herrmann
BRIEF

published on 10/25/2024 at 16:05, 26 days 18 hours ago

Pentixapharm Holding AG Announces Leadership Changes

Leadership Changes Supervisory Board Pentixapharm Dr. Hakim Bouterfa Dr. Dirk Pleimes
PRESS RELEASE

published on 10/25/2024 at 16:00, 26 days 18 hours ago

Pentixapharm Holding AG: Upcoming Changes in the Management and Supervisory Boards of the Pentixapharm Group
Pentixapharm Holding AG announces upcoming changes in management and supervisory boards, including CEO transition and new board appointments

CEO Transition Supervisory Board Management Changes Pentixapharm Holding AG Nuclear Medicine Specialist

Accesswire

Published on 11/21/2024 at 10:03, 38 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 41 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 41 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 6 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 16 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:30, 11 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 36 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 38 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 41 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 41 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 43 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 21 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 56 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 56 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE